This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Phase III Data Show Investigational Compound Empagliflozin Plus Insulin Significantly Reduced HbA1c In Adults With Type 2 Diabetes

RIDGEFIELD, Conn. and INDIANAPOLIS, June 22, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced results of a 78-week phase III clinical trial of the investigational agent empagliflozin* as add-on to basal insulin in adults with type 2 diabetes (T2D). The study, presented at the American Diabetes Association 73rd Scientific Sessions ®, showed that empagliflozin 10 mg or 25 mg, plus insulin, produced statistically significant reductions in HbA 1c (average blood glucose) compared with insulin alone at the study's primary endpoint, week 18, as well as at week 78. 1

Empagliflozin is a member of the sodium glucose co-transporter-2 (SGLT2) inhibitor class of compounds, and is being investigated for the reduction of blood glucose levels in adults with T2D. The emerging SGLT2 inhibitor class removes excess glucose through the urine by blocking glucose re-absorption by the kidney.

"This study is part of the Boehringer Ingelheim and Lilly Diabetes alliance's clinical program designed to examine empagliflozin as an add-on therapy to a broad range of existing treatments for people with type 2 diabetes," said Christophe Arbet-Engels, MD, PhD, vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc.

Results of the study with empagliflozin as add-on to basal insulin in people with T2D included the following:
  • Placebo-adjusted reductions in HbA 1c for empagliflozin 10 mg and 25 mg by 0.6 percent and 0.7 percent (p<0.001), respectively, at week 18, and by 0.5 percent and 0.6 percent, respectively, at week 78 (p<0.001). 1 The study included an 18-week fixed insulin dose period, after which the dose was adjusted at investigator discretion. 1
  • At week 78, the placebo-adjusted change in required daily insulin dose was decreased by 6.7 International Units (IU) and 6.0 IU for empagliflozin 10 mg (p=0.002) and 25 mg (p=0.009), respectively. 1

Drug-related adverse events were reported by 39 percent and 44 percent of patients on empagliflozin 10 mg and 25 mg, respectively, and by 31 percent of patients on placebo. Hypoglycemia was reported in 36 percent of patients on empagliflozin 10 mg and 25 mg, and by 35 percent on placebo. Two patients on empagliflozin 25 mg required assistance to treat the hypoglycemic event. Adverse events consistent with urinary tract infection were reported in 15 percent, 12 percent and 9 percent of patients on empagliflozin 10 mg, 25 mg and placebo, respectively. Adverse events consistent with genital infection were reported in 8 percent, 5 percent and 2 percent of patients on empagliflozin 10 mg, 25 mg and placebo, respectively. 1

About the StudyThe 78-week, randomized, double-blind, placebo-controlled trial investigated the safety and efficacy of empagliflozin as an add-on compound in adults with T2D on basal insulin. Patients were randomized to receive empagliflozin 10 mg (n=169), empagliflozin 25 mg (n=155) or placebo (n=170). Basal insulin dose remained constant for the first 18 weeks. Thereafter, adjustments were allowed at investigator discretion. Primary endpoint was change from baseline in HbA 1c at week 18. Key secondary endpoints were changes from baseline in insulin dose and HbA 1c at week 78. 1

About the Empagliflozin Phase III Clinical Trial ProgramEmpagliflozin is being investigated in adults with T2D in a phase III clinical trial program that has enrolled more than 14,500 patients. This program includes more than 10 multinational clinical trials, including a large cardiovascular outcomes trial.

About DiabetesApproximately 25.8 million Americans 2 and an estimated 371 million people worldwide 3 have type 1 or type 2 diabetes. T2D is the most common type, accounting for an estimated 90 to 95 percent of all diabetes cases. 2 Diabetes is a chronic condition that occurs when the body does not properly produce or use the hormone insulin. 4 Diabetes was estimated to cost the U.S. $245 billion in direct medical costs and reduced productivity in 2012. 5

Boehringer Ingelheim and Eli Lilly and Company In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an alliance in the field of diabetes that centers on three compounds representing several of the largest diabetes treatment classes. This alliance leverages the companies' strengths as two of the world's leading pharmaceutical companies, combining Boehringer Ingelheim's solid track record of research-driven innovation and Lilly's innovative research, experience, and pioneering history in diabetes. By joining forces, the companies demonstrate commitment in the care of patients with diabetes and stand together to focus on patient needs. Find out more about the alliance at or

About Boehringer Ingelheim Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation ( Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim has a demonstrated commitment to corporate social responsibility. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,084.49 +33.74 0.20%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,830.47 +19.6820 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs